Epicardial Ablation for Ventricular Tachycardia
Ventricular tachycardia (VT) is a major cause of sudden cardiac death and recurrent implantable cardioverter-defibrillator (ICD) therapy in patients with structural heart disease. Catheter ablation has become an established treatment for drug-refractory VT, electrical storm, and frequent appropriate ICD shocks. Although many arrhythmogenic substrates can be reached from the endocardium, a clinically important proportion extends through the ventricular wall or is predominantly located on the epicardial surface.
Epicardial VT ablation provides direct access to substrate that may be concealed from endocardial mapping. The approach is especially relevant in arrhythmogenic right ventricular cardiomyopathy, nonischemic cardiomyopathy, cardiac sarcoidosis, Chagas disease, and selected cases of ischemic cardiomyopathy. It can be performed as a planned first-line strategy, a combined endocardial–epicardial procedure, or a staged intervention after failed endocardial ablation.
The technique requires careful patient selection, detailed imaging, coordinated anesthesia, and expertise in pericardial access and complication management. Outcomes depend on the underlying disease, scar distribution, procedural timing, and the ability to eliminate both clinical VT and the broader arrhythmogenic substrate.
Why Epicardial Substrate Matters
The ventricular myocardium is not electrically uniform. Fibrosis, fatty replacement, inflammation, and scar can involve the subepicardial layers while leaving the endocardium relatively intact. In these patients, endocardial electrograms may show little abnormality even when the epicardial surface contains extensive low-voltage tissue, late potentials, fractionated signals, or conduction channels capable of sustaining re-entry.
Epicardial involvement is common in nonischemic cardiomyopathy, where scar often follows a mid-myocardial or subepicardial distribution. In arrhythmogenic right ventricular cardiomyopathy, the so-called triangle of dysplasia may include the epicardial right ventricular outflow tract and inferior wall. Patients with inferolateral subepicardial scar on cardiac magnetic resonance imaging may also have VT circuits that require an epicardial approach.
The surface electrocardiogram can provide useful clues. A delayed intrinsicoid deflection in the inferior or lateral leads, a pseudo-delta wave, prolonged maximum deflection index, or a slurred initial QRS may suggest epicardial origin. These markers are imperfect, however, and should be interpreted alongside imaging, prior ablation findings, and the clinical VT morphology.
Patient Selection And Procedural Planning
A comprehensive evaluation begins with the clinical history, 12-lead ECG, ICD recordings, echocardiography, cardiac magnetic resonance imaging, and, when appropriate, computed tomography or positron emission tomography. Imaging helps define scar location, ventricular anatomy, coronary artery relationships, phrenic nerve position, and the possibility of active inflammation. Treating an inflammatory process or optimizing heart failure may be necessary before ablation.
Epicardial access may be considered after failed endocardial ablation, when the suspected substrate is predominantly epicardial, or when prior mapping has demonstrated an inaccessible or intramural circuit. A combined procedure can reduce the risk of leaving untreated substrate between the endocardial and epicardial surfaces. The decision should account for hemodynamic status, anticoagulation, prior cardiac surgery, pericardial adhesions, and the operator’s experience.
Patients should be counselled about the additional risks of pericardial puncture and ablation near vital structures. These include hemopericardium, coronary artery injury, phrenic nerve damage, pericarditis, diaphragmatic injury, and late constrictive pericarditis. A surgical backup plan and access to blood products are prudent, particularly in patients with severe ventricular dysfunction or extensive scar.
Pericardial Access And Mapping
Subxiphoid percutaneous access is commonly performed with fluoroscopic, echocardiographic, or combined guidance. A micropuncture technique can reduce the risk of inadvertent injury during needle advancement. Once the pericardial space is entered, a guidewire and sheath are introduced, followed by diagnostic mapping and ablation catheters. Previous surgery or inflammation can produce adhesions that limit catheter movement and increase procedural complexity.
Epicardial mapping identifies low-voltage regions, abnormal potentials, isolated late potentials, and local abnormal ventricular activities. Pace mapping, entrainment, activation mapping, and substrate-based strategies are used according to the patient’s rhythm stability. When VT is poorly tolerated, substrate modification in sinus rhythm can target conducting channels within scar, while pace mapping and imaging help define likely exit sites.
Ablation must be performed with awareness of the coronary arteries, phrenic nerve, and extracardiac structures. Coronary angiography is often used before delivering radiofrequency energy near a major vessel. High-output pacing can help identify phrenic nerve capture, although the absence of capture does not eliminate risk. Irrigated radiofrequency catheters are widely used, but power, contact force, irrigation, and lesion duration require adjustment because epicardial fat can limit energy delivery and obscure effective lesion formation.
Techniques And Expected Outcomes
The procedural endpoint is usually a combination of clinical VT noninducibility, elimination of abnormal electrograms, and modification of the arrhythmogenic substrate. Some centers use a stepwise strategy: endocardial mapping first, followed by epicardial mapping when the endocardial findings do not explain the clinical arrhythmia. Others use simultaneous or closely staged access when preprocedural evidence strongly suggests epicardial disease.
Acute success rates vary substantially because published series include different diseases, definitions, and follow-up periods. In experienced centers, complete procedural success is often achievable in a majority of carefully selected patients. Long-term freedom from recurrent VT is lower than acute noninducibility because scar progression, incomplete lesion formation, and new arrhythmogenic pathways can produce later events.
| Clinical setting | Typical role of epicardial ablation | Main outcome considerations | Important limitations |
|---|---|---|---|
| Nonischemic cardiomyopathy | Frequently used with endocardial ablation when scar is subepicardial or intramural | Reduction in VT recurrence and ICD therapies in selected patients | Broad, patchy scar and disease progression can cause late recurrence |
| Arrhythmogenic right ventricular cardiomyopathy | Often considered early for extensive right ventricular epicardial substrate | Improved substrate modification and lower recurrence in experienced programs | Risk of right coronary or phrenic nerve injury; recurrence remains possible |
| Ischemic cardiomyopathy | Usually reserved for failed endocardial ablation or unusual epicardial circuits | Can address residual channels and recurrent VT | Epicardial substrate is less common; coronary anatomy may restrict ablation |
| Cardiac sarcoidosis or inflammatory disease | May be used when scar persists after medical treatment and endocardial ablation | Results depend heavily on control of inflammation | Active disease can create new substrate and complicate interpretation |
| Electrical storm | Used as part of urgent rhythm control when shocks persist despite medication | May reduce VT burden and stabilize the clinical course | Hemodynamic instability, sedation, and procedural risk may be substantial |
The benefit should be measured clinically, not solely by acute procedural endpoints. Reductions in VT burden, ICD shocks, hospitalization, and antiarrhythmic drug exposure are meaningful outcomes even when isolated late recurrences occur. Mortality is influenced by ventricular function, comorbidity, and the underlying myocardial disease, so ablation should be integrated with ICD management, heart failure treatment, and disease-specific therapy.
Safety, Complications, And Follow-Up
Pericardial bleeding is the most immediate concern after epicardial access. Persistent hypotension, rising pericardial pressure, or an enlarging effusion requires rapid evaluation and treatment. Intrapericardial steroids and colchicine are sometimes used to reduce postprocedural inflammation, although practice varies according to institutional protocols and patient factors.
Other complications include coronary artery stenosis or thrombosis, phrenic nerve palsy, pleural injury, abdominal organ trauma, and infection. Delayed pericarditis can cause significant chest pain and fever, while rare cases of constrictive pericarditis may present later. Close observation, echocardiography, symptom review, and appropriate laboratory testing are important during the early postprocedural period.
Follow-up should include ICD interrogation, assessment of antiarrhythmic therapy, ventricular function, and recurrent symptoms. A recurrent VT episode does not automatically indicate procedural failure; its morphology, cycle length, burden, and relationship to the treated substrate should be reviewed. Repeat mapping may be appropriate when recurrence is frequent, while selected patients can be managed with medication adjustment and device programming.
Evolving Tools And Evidence
High-density mapping, multipolar catheters, three-dimensional electroanatomic systems, and integration with cardiac magnetic resonance imaging are improving substrate characterization. These tools may identify narrow conduction corridors and help distinguish viable myocardium from dense scar. Imaging-guided strategies are particularly valuable when the substrate is extensive or when the clinical VT cannot be induced safely.
Research is also examining bipolar ablation, needle-based or needle-assisted techniques, surgical hybrid procedures, and noninvasive stereotactic body radiation therapy. These approaches may be relevant for intramural or inaccessible substrate, but their indications, durability, and safety profiles continue to develop. Epicardial access remains an important component of treatment even as alternative energy sources and mapping technologies expand.
The evidence base is composed largely of observational studies, single-center experiences, and selected comparative analyses. Randomized trials are difficult because patients have varied diseases and urgent clinical presentations. Interpretation should therefore consider referral bias, operator expertise, differences in endpoint definitions, and the use of repeat procedures.
The themed collections available through the Journal of Arrhythmia can help clinicians and trainees follow developments in ventricular arrhythmia ablation, imaging, devices, and electrophysiology. Reviewing current guidelines alongside contemporary procedural studies is essential when translating emerging techniques into practice.
Recommendations For Clinical Practice
Epicardial intervention should be approached as a specialized therapy within a broader ventricular arrhythmia program. Practical priorities include:
- Use cardiac imaging, ECG features, prior ablation data, and disease phenotype to estimate the likelihood of epicardial substrate.
- Plan coronary and phrenic nerve assessment before energy delivery in anatomically vulnerable regions.
- Perform the procedure in an experienced center with surgical, anesthesia, imaging, and critical care support.
- Define acute endpoints in advance, including clinical VT noninducibility and meaningful substrate modification.
- Continue long-term ICD, heart failure, antiarrhythmic, and disease-specific management after ablation.
Multidisciplinary discussion is particularly valuable for patients with severe ventricular dysfunction, inflammatory cardiomyopathy, previous cardiac surgery, or recurrent VT after more than one procedure. Shared decision-making should address the likelihood of recurrence as well as the potential to reduce shocks and improve quality of life.
Translating Evidence Into Care
Epicardial mapping and ablation have changed the treatment strategy for ventricular tachycardia arising from substrate that cannot be adequately treated from inside the heart. The approach offers substantial value in selected patients, but its success depends on accurate localization, careful pericardial access, protection of adjacent structures, and continued management of the underlying cardiomyopathy.
Clinicians seeking further evidence can review published studies on catheter ablation, ventricular arrhythmias, and implantable devices, while authors and readers may contact the editorial office regarding relevant research, educational material, or emerging clinical experience. Continued collaboration between electrophysiologists, imaging specialists, surgeons, and heart failure teams will be central to improving durable outcomes.